Trials / Completed
CompletedNCT01724112
Study of the Efficacy and Safety of LY2940094 in Participants With Major Depressive Disorder (MDD)
8-Week, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multi-center Study of the Efficacy and Safety of LY2940094 Administered Once Daily in Patients With Major Depressive Disorder (MDD)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 136 (actual)
- Sponsor
- BlackThorn Therapeutics, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
This study will determine the efficacy, safety, and tolerability of a 40 milligrams (mg) once-daily (QD) dose of LY2940094 for 8 weeks in participants with MDD.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LY2940094 | Administered orally |
| DRUG | Placebo | Administered orally |
Timeline
- Start date
- 2012-11-01
- Primary completion
- 2014-03-01
- Completion
- 2014-03-01
- First posted
- 2012-11-09
- Last updated
- 2017-02-03
Locations
10 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01724112. Inclusion in this directory is not an endorsement.